Clinical trial
A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2101
NCT05923918 is registered in ClinicalTrials.gov with Pharmbio Korea Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2101
- Lead sponsor
- Pharmbio Korea Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- June 30, 2023
- Completion date
- June 30, 2024
- Enrollment
- 246 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colonic diseases, digestive system disease, gastrointestinal disease, intestinal disease